Literature DB >> 8806522

The Sendai virus V protein interacts with the NP protein to regulate viral genome RNA replication.

S M Horikami1, S Smallwood, S A Moyer.   

Abstract

The interactions of Sendai virus proteins required for viral RNA synthesis have been characterized both by the yeast two-hybrid system and through the use of glutathione S-transferase (gst)-viral fusion proteins synthesized in mammalian cells. Using the two-hybrid system we have confirmed the previously identified P-L (RNA polymerase), NPo-P (encapsidation substrate), and P-P complexes and now demonstrate NP-NP and NPo-V protein interactions. Expression of gstP and P proteins and binding to glutathione-Sepharose beads as a measure of complex formation confirmed the P-P interaction. The P-gstP binding occurred only on expression of the proteins in the same cell and was mapped to amino acids 345-411. We also show that full-length and deletion gstV and gstW proteins bound NPo protein when these sets of proteins were coexpressed and have identified one required region from amino acids 78-316. Neither gstV nor gstW bound NP assembled into nucleocapsids. Furthermore, both V and W proteins lacking the N-terminal 77 amino acids inhibited DI-H genome replication in vitro, showing the biological relevance of the remaining region. We propose that the specific inhibition of genome replication by V and W proteins occurs through interference with either the formation or the use of the NPo-P encapsidation substrate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8806522     DOI: 10.1006/viro.1996.0435

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  33 in total

1.  Dissection of individual functions of the Sendai virus phosphoprotein in transcription.

Authors:  M C Bowman; S Smallwood; S A Moyer
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs.

Authors:  K J Lee; I S Novella; M N Teng; M B Oldstone; J C de La Torre
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  The C-terminal 88 amino acids of the Sendai virus P protein have multiple functions separable by mutation.

Authors:  Jeffery Tuckis; Sherin Smallwood; Joyce A Feller; Sue A Moyer
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Dynamics of viral RNA synthesis during measles virus infection.

Authors:  Sébastien Plumet; W Paul Duprex; Denis Gerlier
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

5.  Complete genome sequence of avian paramyxovirus type 3 reveals an unusually long trailer region.

Authors:  Sachin Kumar; Baibaswata Nayak; Peter L Collins; Siba K Samal
Journal:  Virus Res       Date:  2008-08-15       Impact factor: 3.303

6.  The NS1 protein of human respiratory syncytial virus is a potent inhibitor of minigenome transcription and RNA replication.

Authors:  P L Atreya; M E Peeples; P L Collins
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

7.  Intermolecular Interactions of Chrysanthemum virus B Coat Protein: Implications for Capsid Assembly.

Authors:  Lakhmir Singh; Vipin Hallan; Aijaz A Zaidi
Journal:  Indian J Virol       Date:  2011-09-13

8.  Rinderpest viruses lacking the C and V proteins show specific defects in growth and transcription of viral RNAs.

Authors:  M D Baron; T Barrett
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

9.  Naturally occurring substitutions in the P/V gene convert the noncytopathic paramyxovirus simian virus 5 into a virus that induces alpha/beta interferon synthesis and cell death.

Authors:  Elizabeth K Wansley; Griffith D Parks
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist.

Authors:  Zhuhui Huang; Sateesh Krishnamurthy; Aruna Panda; Siba K Samal
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.